Nerve Stimulation Device Helps Relieve Lower Back Pain
By HospiMedica International staff writers Posted on 26 Jul 2016 |
Image: The Aleve Direct Therapy device (Photo courtesy of Bayer HealthCare).
An innovative, drug-free device uses transcutaneous electrical nerve stimulation (TENS) for temporary relief of muscular pain in the lower back.
The Bayer Aleve Direct Therapy device is a high quality, durable pad that provides a high level of TENS stimulation waveform intensity, which both blocks the transmission of pain and stimulates production of endorphins, the body's natural pain reducing chemicals. The device can be worn discretely and comfortably throughout the day on the user's lower back, even during some physical activities, and can be controlled via a wireless remote control. Users go through a three-stage therapy session that can be repeated as necessary, with 30-minute breaks between sessions.
The first stage, during which high-frequency stimulation first initiates pain suppression, lasts five minutes. A 20-minute second stage offers low-frequency stimulation to increase the release of endorphins. The final stage lasts an additional five minutes and offers the same high-frequency stimulation as stage one, to maintain the feeling of pain relief. The Bayer Aleve Direct Therapy device is a product of Bayer HealthCare (Leverkusen, Germany), and has been approved by the U.S. Food and Drug Administration (FDA).
“Aleve Direct Therapy puts controllable TENS technology in consumers hands without having to visit the doctor. It provides high intensity of power and its wireless remote control makes it easy to adjust the power of intensity to fit the user's needs,” said Andre Schmidt, vice president of U.S. medical affairs for Bayer’s consumer health division. “We are pleased to be able to provide this safe, drug-free and convenient self-care option to help consumers get the relief they need from lower back pain.”
TENS is one of the most commonly used forms of electroanalgesia for various types of conditions, such as lower back, myofascial, arthritic, neurogenic, visceral, and postsurgical pain, as well as bladder incontinence. TENS produces neuromodulation by presynaptic inhibition in the dorsal horn of the spinal cord, endogenous pain control via endorphins, enkephalins, and dynorphins, direct inhibition of an abnormally excited nerve, and restoration of afferent input. The mechanism of the analgesia produced by TENS is explained by gate-control theory.
Related Links:
Bayer HealthCare
The Bayer Aleve Direct Therapy device is a high quality, durable pad that provides a high level of TENS stimulation waveform intensity, which both blocks the transmission of pain and stimulates production of endorphins, the body's natural pain reducing chemicals. The device can be worn discretely and comfortably throughout the day on the user's lower back, even during some physical activities, and can be controlled via a wireless remote control. Users go through a three-stage therapy session that can be repeated as necessary, with 30-minute breaks between sessions.
The first stage, during which high-frequency stimulation first initiates pain suppression, lasts five minutes. A 20-minute second stage offers low-frequency stimulation to increase the release of endorphins. The final stage lasts an additional five minutes and offers the same high-frequency stimulation as stage one, to maintain the feeling of pain relief. The Bayer Aleve Direct Therapy device is a product of Bayer HealthCare (Leverkusen, Germany), and has been approved by the U.S. Food and Drug Administration (FDA).
“Aleve Direct Therapy puts controllable TENS technology in consumers hands without having to visit the doctor. It provides high intensity of power and its wireless remote control makes it easy to adjust the power of intensity to fit the user's needs,” said Andre Schmidt, vice president of U.S. medical affairs for Bayer’s consumer health division. “We are pleased to be able to provide this safe, drug-free and convenient self-care option to help consumers get the relief they need from lower back pain.”
TENS is one of the most commonly used forms of electroanalgesia for various types of conditions, such as lower back, myofascial, arthritic, neurogenic, visceral, and postsurgical pain, as well as bladder incontinence. TENS produces neuromodulation by presynaptic inhibition in the dorsal horn of the spinal cord, endogenous pain control via endorphins, enkephalins, and dynorphins, direct inhibition of an abnormally excited nerve, and restoration of afferent input. The mechanism of the analgesia produced by TENS is explained by gate-control theory.
Related Links:
Bayer HealthCare
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration